Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7853682rdf:typepubmed:Citationlld:pubmed
pubmed-article:7853682lifeskim:mentionsumls-concept:C1516634lld:lifeskim
pubmed-article:7853682lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:7853682lifeskim:mentionsumls-concept:C1521725lld:lifeskim
pubmed-article:7853682lifeskim:mentionsumls-concept:C0246584lld:lifeskim
pubmed-article:7853682lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:7853682lifeskim:mentionsumls-concept:C1521738lld:lifeskim
pubmed-article:7853682pubmed:issue11lld:pubmed
pubmed-article:7853682pubmed:dateCreated1995-3-14lld:pubmed
pubmed-article:7853682pubmed:abstractTextWe conducted a pharmacokinetic and clinical studies on cefozopran (CZOP), a new cephem antibiotic for injection. 1. Changes in serum levels of the agent after intravenous bolus injection at a dose of 20 mg/kg to 4 pediatric patients (age: 5-10 years) were observed. The levels at 30 minutes after injection were 32.9-73.4 micrograms/ml average: 55.4 +/- 18.1 micrograms/ml), then the levels gradually decreased with half-lives of 1.67-2.24 hours (average: 1.85 +/- 0.27 hours) to 0.8-1.8 micrograms/ml (average: 1.2 +/- 0.4 micrograms/ml) at 8 hours after injections. Urinary levels reached at the maximum as, 1,773-3,450 micrograms/ml (average: 2,693 +/- 698 micrograms/ml) within 0-2 hours or 2-4 hours after injection, and recovery rates from urine in the first 8 hours after injection were 55.4-91.1% (average: 71.6 +/- 16.8%). 2. Transition to cerebrospinal fluid was examined in cases with purulent meningitis and aseptic meningoencephalitis. In the meningitis case, the level in cerebrospinal fluid 1 hour after administration was 8.8 micrograms/ml in the second day after the start of 4 times a day intravenous bolus injections with 42.5 mg/kg at each dose; The ratio of the drug level in cerebrospinal fluid to that in serum was 24.0%. In the meningoencephalitis, the levels in cerebrospinal fluid 1 hour after administrations were 1.1 micrograms/ml and 1.5 micrograms/ml in the second and the sixth days respectively, after the start of 4 times a day intravenous bolus injections with 50 mg/kg at each dose; the ratio of the levels in cerebrospinal fluid to those in sera were 0.93% and 2.41% respectively, at the second and the sixth day. 3. CZOP was clinically evaluated in 29 cases (ages: 2 months to 15 years) of pediatric infectious diseases. The agent was administered 3-4 times daily with 17-50 mg/kg at each dose, continued for 5-13 days. Total doses were 1.95-24.05 g. Clinical efficacy was evaluated in a total of 28 cases (1 case of purulent meningitis, 2 cases of acute purulent tonsillitis, 20 cases of acute pneumonia, 3 cases of urinary tract infections, 1 case of purulent lymphadenitis in cervical part and 1 case of cellulitis in face); The efficacies were "excellent" in 22 cases and "good" in 6 cases.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:7853682pubmed:languagejpnlld:pubmed
pubmed-article:7853682pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7853682pubmed:citationSubsetIMlld:pubmed
pubmed-article:7853682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7853682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7853682pubmed:statusMEDLINElld:pubmed
pubmed-article:7853682pubmed:monthNovlld:pubmed
pubmed-article:7853682pubmed:issn0368-2781lld:pubmed
pubmed-article:7853682pubmed:authorpubmed-author:NakamuraHHlld:pubmed
pubmed-article:7853682pubmed:authorpubmed-author:WatanabeYYlld:pubmed
pubmed-article:7853682pubmed:authorpubmed-author:IwaiNNlld:pubmed
pubmed-article:7853682pubmed:authorpubmed-author:MiyaziAAlld:pubmed
pubmed-article:7853682pubmed:authorpubmed-author:TanedaYYlld:pubmed
pubmed-article:7853682pubmed:issnTypePrintlld:pubmed
pubmed-article:7853682pubmed:volume47lld:pubmed
pubmed-article:7853682pubmed:ownerNLMlld:pubmed
pubmed-article:7853682pubmed:authorsCompleteYlld:pubmed
pubmed-article:7853682pubmed:pagination1521-35lld:pubmed
pubmed-article:7853682pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:meshHeadingpubmed-meshheading:7853682-...lld:pubmed
pubmed-article:7853682pubmed:year1994lld:pubmed
pubmed-article:7853682pubmed:articleTitle[Pharmacokinetic and clinical evaluation of cefozopran in the pediatric field].lld:pubmed
pubmed-article:7853682pubmed:affiliationDepartment of Pediatrics, Meitetsu Hospital.lld:pubmed
pubmed-article:7853682pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7853682pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7853682pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:7853682pubmed:publicationTypeCase Reportslld:pubmed